NBIX gets FDA IND acceptance for NBI-1117567 Phase 2 Alzheimer’s cognition
Neurocrine Biosciences, Nxera Pharma’s partner, received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting Alzheimer’s cognition.
Story updates
07:37:50 AM UTC
SquawkNews
Nxera Pharma Co., Ltd.- Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.